A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer

Part of paid clinical trials in Los Angeles, California.

Sponsor
Verastem, Inc.
Study ID
NCT07659782
Phase
PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • VS-7375 — DRUG
    Taken by mouth

Study Details

This study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab in patients with metastatic KRAS G12D - mutated Non-Small Cell Lung Cancer

Key Dates

First listed
Jun 22, 2026
Start date
Jun 30, 2026
Status verified
Jul 2026
Primary completion
Jun 30, 2027
Completion
Dec 31, 2028

Study Design

Enrollment
105 participants (estimated)
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT

Arms

  • Experimental: VS-7375 Monotherapy 2L/3L
    2L/3L VS-7375 dose
  • Experimental: VS-7375 Monotherapy 2L/3L Preferred Dose
    2L/3L Preferred VS-7375 dose
  • Experimental: 2L-4L with brain metastasis
    2L-4L VS-7375 dose

Primary Outcome Measure

Confirmed ORR by blinded independent central review (BICR) per RESIST v1.1 [ Time Frame: 6 months ]

Central Contacts

Locations (3)

FacilityCityStateZIPSite coordinators
START LALos AngelesCalifornia90025
Hope Team Distribution List
[email protected]
4244651820
Navid Hafez, MD (PRINCIPAL_INVESTIGATOR)
START New JerseyEast BrunswickNew Jersey08816
Emily Lichtenstein
[email protected]
7324264750
Bruno Fang, MD (PRINCIPAL_INVESTIGATOR)
START Fort WorthFort WorthTexas76104
Hope Team
[email protected]
6823503010
Salwan Almutar, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Los Angeles, CA

By condition
Lung cancer
By specialty
OncologyLung oncologyLung disease
By research site
START LA· Los Angeles, CASTART New Jersey· East Brunswick, NJSTART Fort Worth· Fort Worth, TX

Related Studies